Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-17), Syndax Pharmaceuticals's Beta is 1.7387.
Syndax Pharmaceuticals (STU:1T3) Beta Explanation
Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Syndax Pharmaceuticals's Beta, along with its competitors' market caps and Beta data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syndax Pharmaceuticals Beta vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's Beta distribution charts can be found below:
* The bar in red indicates where Syndax Pharmaceuticals's Beta falls into.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.
Syndax Pharmaceuticals (STU:1T3) has a Beta of 1.7387 as of Jul. 17, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Syndax Pharmaceuticals and its competitors.
Is Syndax Pharmaceuticals' Beta too high?
Syndax Pharmaceuticals' current Beta is 1.7387. Overall, Syndax Pharmaceuticals has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Syndax Pharmaceuticals' Beta compare to IOVA and GLUE?
Syndax Pharmaceuticals' Beta of 1.7387 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Syndax Pharmaceuticals and its competitors. Syndax Pharmaceuticals's current Beta is 1.7387. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syndax Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Syndax Pharmaceuticals (STU:1T3) is currently considered Possible Value Trap. The stock's GF Value™ is €698.80, compared to a current price of €19.84 — trading 97.2% below its estimated fair value. The current Beta is 1.7387. Syndax Pharmaceuticals' overall GF Score™ is 34/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Syndax Pharmaceuticals (STU:1T3), the current Beta is 1.7387 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syndax Pharmaceuticals (STU:1T3) Overvalued in 2026?
Based on GuruFocus' analysis, Syndax Pharmaceuticals stock appears to be undervalued.
The current stock price of €19.84 is trading 97.2% below its estimated GF Value™ of €698.80.
GuruFocus considers Syndax Pharmaceuticals to be Possible Value Trap.
Key valuation signals for STU:1T3:
Beta: 1.7387
GF Value™: €698.80 vs. price of €19.84 (97.2% below fair value)
No single metric tells the full story. See the STU:1T3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
34GF Score
Get the complete analysis for STU:1T3
Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1T3 has been successfully added to your 
